NASDAQ:FTSV - Forty Seven Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$95.51
+0.30 (1.20%)
Get New Forty Seven Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FTSV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FTSV

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Forty Seven in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $95.51.
N/A
The current consensus among 0 polled investment analysts is to n/a stock in Forty Seven. This rating has held steady since February 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/26/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
1/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 0 sell ratings
4/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 0 sell ratings
7/22/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 0 sell ratings
10/20/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 0 sell ratings
1/18/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/4/2020MizuhoDowngradeBuy ➝ Neutral$95.50Low
i
Rating by Mara Goldstein at Mizuho
3/3/2020GuggenheimDowngradeBuy ➝ NeutralLow
i
Rating by Etzer Darout at Guggenheim
3/3/2020SunTrust BanksDowngradeBuy ➝ Hold$55.00 ➝ $95.50Low
i
3/3/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$45.00 ➝ $95.50Low
i
3/3/2020Canaccord GenuityDowngradeBuy ➝ HoldLow
i
3/2/2020Roth CapitalDowngradeBuy ➝ Neutral$95.50Medium
i
Rating by Anthony Butler at Roth Capital
3/2/2020HC WainwrightDowngradeBuy ➝ Neutral$95.50High
i
Rating by Swayampakula Ramakanth at HC Wainwright
2/12/2020MizuhoBoost Price TargetBuy$37.00 ➝ $53.00Low
i
Rating by Mara Goldstein at Mizuho
2/4/2020GuggenheimReiterated RatingBuy$54.00High
i
Rating by Etzer Darout at Guggenheim
1/26/2020MizuhoReiterated RatingBuy$37.00Low
i
Rating by Mara Goldstein at Mizuho
1/22/2020HC WainwrightReiterated RatingBuy$51.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
1/17/2020OppenheimerBoost Price TargetOutperform$60.00 ➝ $35.00Low
i
1/13/2020SunTrust BanksInitiated CoverageBuy$55.00Low
i
1/10/2020MizuhoReiterated RatingBuy$37.00High
i
Rating by Mara Goldstein at Mizuho
1/7/2020Roth CapitalBoost Price TargetBuy$35.00 ➝ $55.00High
i
12/11/2019GuggenheimReiterated RatingBuy$20.00 ➝ $48.00Medium
i
Rating by Etzer Darout at Guggenheim
12/10/2019Roth CapitalBoost Price TargetBuy$28.00 ➝ $35.00Medium
i
12/10/2019HC WainwrightReiterated RatingBuy$21.00 ➝ $36.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
12/10/2019Morgan StanleyBoost Price TargetOverweight$17.00 ➝ $45.00High
i
12/10/2019CitigroupBoost Price TargetOutperform$20.00 ➝ $35.00High
i
12/10/2019BTIG ResearchReiterated RatingBuy$40.00High
i
12/10/2019MizuhoReiterated RatingBuy$18.00 ➝ $37.00High
i
12/5/2019Credit Suisse GroupReiterated RatingOutperform$15.00 ➝ $18.00High
i
11/20/2019GuggenheimInitiated CoverageBuy$20.00High
i
Rating by Etzer Darout at Guggenheim
11/13/2019HC WainwrightReiterated RatingBuy$21.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/12/2019MizuhoReiterated RatingBuy$18.00High
i
9/11/2019MizuhoInitiated CoverageBuy$18.00High
i
8/14/2019OppenheimerLower Price Target$35.00 ➝ $20.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
7/12/2019HC WainwrightSet Price TargetBuy$21.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
5/29/2019Roth CapitalInitiated CoverageBuy ➝ Buy$18.00 ➝ $28.00Low
i
Rating by T. Butler at Roth Capital
5/14/2019HC WainwrightSet Price TargetBuy$21.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
4/12/2019GuggenheimInitiated CoverageBuyHigh
i
3/29/2019HC WainwrightReiterated RatingBuy$21.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
3/19/2019OppenheimerReiterated RatingBuyMedium
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
2/1/2019FIG PartnersInitiated CoverageBuy$30.00Low
i
1/23/2019HC WainwrightSet Price TargetBuy$21.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
1/14/2019HC WainwrightReiterated RatingBuy$21.00Low
i
Rating by S. Ramakanth at HC Wainwright
1/11/2019OppenheimerSet Price TargetBuy$35.00Low
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
12/21/2018BTIG ResearchInitiated CoverageBuy ➝ Buy$36.00Low
i
12/9/2018HC WainwrightInitiated CoverageBuy$21.00 ➝ $17.66Low
i
Rating by S. Ramakanth at HC Wainwright
11/30/2018HC WainwrightInitiated CoverageBuy ➝ Buy$21.00High
i
Rating by S. Ramakanth at HC Wainwright
10/11/2018Morgan StanleyBoost Price TargetOverweight$25.00 ➝ $26.00High
i
7/23/2018OppenheimerInitiated CoverageOutperform$35.00High
i
7/23/2018Credit Suisse GroupInitiated CoverageOutperform$24.00Medium
i
7/23/2018Morgan StanleyInitiated CoverageOverweight$25.00High
i
7/23/2018Canaccord GenuityInitiated CoverageBuy$22.00High
i
(Data available from 4/18/2016 forward)
Forty Seven logo
Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $95.51
$95.51
$95.51

50 Day Range

MA: $95.51
$95.51
$95.51

52 Week Range

Now: $95.51
$5.53
$95.51

Volume

N/A

Average Volume

1,606,836 shs

Market Capitalization

$4.60 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4

Frequently Asked Questions

What sell-side analysts currently cover shares of Forty Seven?

The following equities research analysts have issued stock ratings on Forty Seven in the last year:
View the latest analyst ratings for FTSV.

What is the current price target for Forty Seven?

0 Wall Street analysts have set twelve-month price targets for Forty Seven in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Forty Seven in the next year.
View the latest price targets for FTSV.

What is the current consensus analyst rating for Forty Seven?

Forty Seven currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for FTSV.

What other companies compete with Forty Seven?

How do I contact Forty Seven's investor relations team?

Forty Seven's physical mailing address is 1490 O`BRIEN DRIVE SUITE A, MENLO PARK CA, 94025. The company's listed phone number is 650-352-4150 and its investor relations email address is [email protected] The official website for Forty Seven is www.fortyseveninc.com.